Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
McKinsey
Moodys
Express Scripts
Colorcon

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

CONRAY Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Conray patents expire, and what generic alternatives are available?

Conray is a drug marketed by Liebel-flarsheim and Mallinckrodt and is included in four NDAs.

The generic ingredient in CONRAY is iothalamate sodium. There is one drug master file entry for this compound. Additional details are available on the iothalamate sodium profile page.

Drug patent expirations by year for CONRAY
Drug Prices for CONRAY

See drug prices for CONRAY

Pharmacology for CONRAY
Synonyms for CONRAY
1-Deoxy-1-(methylamino)-D-glucitol 3-(acetylamino)-2,4,6-triiodo-5-((methylamino)carbonyl)benzoate
1-Deoxy-1-(methylamino)-D-glucitol 5-acetamido-2,4,6-triiodo-N-methylisophthalamate (salt)
13087-53-1
16240-57-6
3-acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoic acid; (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol
3-acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoic acid; 6-(methylamino)hexane-1,2,3,4,5-pentol
3-acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoic acid;(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol
3-acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoic acid;6-(methylamino)hexane-1,2,3,4,5-pentol
519-25-5
AC1L19JR
AC1LCVC4
AN-18407
Benzoic acid, 3-(acetylamino)-2,4,6-triiodo-5-((methylamino)carbonyl)-, compd. with 1-deoxy-1-(methylamino)-D-glucitol (1:1)
CHEBI:31714
CHEMBL1201125
Conray (TN)
Conray 280
Conray 30
Conray 43
Conray 60
Conray meglumin
Conray meglumine 282
Contrix 28
Cysto-Conray
Cysto-conray II
D-Glucitol, 1-deoxy-1-(methylamino)-, 3-(acetylamino)-2,4,6-triiodo-5-((methylamino)carbonyl)benzoate (salt)
D01999
EINECS 235-998-9
Iotalamate de methylglucamine
Iotalamate de methylglucamine [French]
Iotalamic acid meglumine
Iothalamate meglumine
Iothalamate meglumine (USP)
Iothalamate Meglumine [USAN]
Iothalamate meglumine [USP]
Iothalamate methylglucamine
Iothalamate methylglucamine salt
Iothalamic acid N-methylgucamine salt
Isophthalamic acid, 5-acetamido-2,4,6-triiodo-N-methyl-, compd. with 1-deoxy-1-(methylamino)-D-glucitol (1:1)
Jotalamsaeure methylglucaminesalz
Jotalamsaeure methylglucaminesalz [German]
LS-85183
Meglumine conray
Meglumine iotalamate
Meglumine Iotalamate Injection
Meglumine iotalamate injection (JP17)
Meglumine iothalamate
Meglumine Iothalamate (BAN)
Meglumine Iothalamate [BAN]
Meglumine isothalamate
Methylglucamine iotalamate
Methylglucamine iothalamate
SCHEMBL180546
UNII-XUW72GOP7W
XUW72GOP7W

US Patents and Regulatory Information for CONRAY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Liebel-flarsheim CONRAY iothalamate meglumine INJECTABLE;INJECTION 013295-001 Approved Prior to Jan 1, 1982 RX Yes Yes   Start Trial   Start Trial   Start Trial
Mallinckrodt CONRAY 400 iothalamate sodium INJECTABLE;INJECTION 014295-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Liebel-flarsheim CONRAY 30 iothalamate meglumine INJECTABLE;INJECTION 016983-001 Approved Prior to Jan 1, 1982 DISCN Yes No   Start Trial   Start Trial   Start Trial
Mallinckrodt CONRAY 325 iothalamate sodium INJECTABLE;INJECTION 017685-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Liebel-flarsheim CONRAY 43 iothalamate meglumine INJECTABLE;INJECTION 013295-002 Approved Prior to Jan 1, 1982 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Merck
Express Scripts
Baxter
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.